Allena Pharmaceuticals, Inc. today announced that company management will virtually participate in H.C. Wainwright’s 23rd Annual Global Investment Conference, being held September 13th – 15th , 2021.
NEWTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) --Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today announced that company management will virtually participate in H.C. Wainwright’s 23rd Annual Global Investment Conference, being held September 13th – 15th, 2021.
Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will virtually participate in a fireside chat at the conference. The pre-recorded discussion will be available on demand beginning 7:00 a.m. ET on September 13th. A recording can also be accessed for 90 days at the link below or via the Allena Pharmaceuticals website within the Investors/Events and Presentations section.
Please see details for the session below:
| Date: | 7:00 a.m. ET |
| Time: | Monday, September 13th, 2021 |
| Webcast: | https://journey.ct.events/view/f1d0178c-8b66-4f9b-bbb4-f26ad0dc2801 |
Management will also be available for 1x1 meetings. If you would like to request a meeting, please email meetings@hcwco.com.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1 multiple-ascending dose study recently completed and a Phase 2a program recently initiated.
Investor Contact
Ashley Robinson
LifeSci Advisors, LLC
617-430-7577
arr@lifesciadvisors.com
Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com
